Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials clinical outcome assessment endpoints workshop (October 15, 2014, Bethesda MD)

Neuro-Oncology

Volumn 18, Issue , 2016, Pages ii26-ii36

  Helfer, Jennifer L ^a   Wen, Patrick Y ^b   Blakeley, Jaishri ^c   Gilbert, Mark R ^d   Armstrong, Terri S ^e  

^a National Brain Tumor Society   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON   (United States)

Author keywords

brain tumor; clinical outcome assessment; endpoints; high grade gliomas; patient reported outcomes

Indexed keywords

CANCER PATIENT; CLINICAL ASSESSMENT; CLINICAL OUTCOME ASSESSMENT; CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; FOOD AND DRUG ADMINISTRATION; GLIOMA; HUMAN; MEDICAL SOCIETY; NATIONAL HEALTH ORGANIZATION; OUTCOME ASSESSMENT; PARAMEDICAL PERSONNEL; SCIENTIST; UNITED STATES; WORKSHOP; BRAIN NEOPLASMS;

TUMOR MARKER;

BIOMARKERS, TUMOR; BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; GLIOMA; HUMANS; NATIONAL CANCER INSTITUTE (U.S.); OUTCOME ASSESSMENT (HEALTH CARE); UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84965126229     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nov270     Document Type: Conference Paper

References (28)

1. Brain Tumor EndpointsWorkshop 2 (clinical outcome assessment) sponsored by Jumpstarting Brain Tumor Drug Development Coalition participant list. http://braintumor.org/wp-content/ assets/BrainTumorEndpoints-Workshop-2-Participant-Final.pdf. Accessed June 12, 2015.
2. Wen PY, Cloughesy TF, Ellingson BM, et al. Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD). Neuro Oncol. 2014;16:vii36-vii47.
3. Ellingson BM, Bendszus M, Boxerman J, et al. Consensus recommendations for a standardized brain tumor imaging protocol in clinical trials. Neuro Oncol. 2015;17(9):1188-1198.
4. Clinical outcome assessment (COA): glossary of terms. http:// www.fda.gov/drugs/developmentapprovalprocess/drugdevelop menttoolsqualificationprogram/ucm370262.htm. Accessed June 12, 2015.
5. Basch E, Geoghegan C, Coons SJ, et al. Patient-reported outcomes in cancer drug development and US regulatory review: perspectives from industry, the Food and Drug Administration, and the patient. JAMA Oncol. 2015;1(3):375-379.
6. Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims. http:// www.fda.gov/downloads/Drugs/Guidances/UCM193282.pdf. Accessed June 12, 2015.
7. Clinical outcome assessment qualification program. http://www. fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopment ToolsQualificationProgram/ucm284077.htm. Accessed June 12, 2015.
8. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14(6):1756-1764.
9. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebocontrolled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799-807.
10. Deisseroth A, Kaminskas E, Grillo J, et al. U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis. Clin Cancer Res. 2012;18(12):3212-3217.
11. FDA label Zytiga (abiraterone acetate). http://www.accessdata. fda.gov/drugsatfda-docs/label/2015/202379s015lbl.pdf. Accessed June 11, 2015.
12. Collins A, Sundararajan V, Brand CA, et al. Clinical presentation and patterns of care for short-term survivors of malignant glioma. J Neurooncol. 2014;119(2):333-341.
13. Molassiotis A, Wilson B, Brunton L, et al. Symptom experience in patients with primary brain tumours: a longitudinal exploratory study. Eur J Oncol Nurs. 2010;14(5):410-416.
14. Taphoorn MJ, Claassens L, Aaronson NK, et al. An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. Eur J Cancer. 2010;46(6): 1033-1040.
15. Sherwood PR, Donovan HS, Given CW, et al. Predictors of employment and lost hours from work in cancer caregivers. Psychooncology. 2008;17(6):598-605.
16. Halkett GK, Lobb EA, Oldham L, et al. The information and support needs of patients diagnosed with high grade glioma. Patient Educ Couns. 2010;79(1):112-119.
17. Madsen K, Poulsen HS. Needs for everyday life support for brain tumour patients' relatives: systematic literature review. Eur J Cancer Care (Engl). 2011;20(1):33-43.
18. Salander P, Bergenheim AT, Henriksson R. How was life after treatment of a brain tumour? Soc Sci Med. 2000;51(4):589-598.
19. Armstrong TS, Wefel JS, Wang M, et al. Net clinical benefit analysis of Radiation Therapy Oncology Group 0525: a phase III trial comparing conventional adjuvant temozolomide with doseintensive temozolomide in patients with newly diagnosed glioblastoma. J Clin Oncol. 2013;31(32):4076-4084.
20. Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699-708.
21. Wefel JS, Cloughesy T, Zazzali JL, et al. Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2011;13(6):660-668.
22. Armstrong TS, Cohen MZ, Eriksen L, et al. Content validity of self-report measurement instruments: an illustration from the development of the brain tumor module of the M.D. Anderson Symptom Inventory. Oncol Nurs Forum. 2005;32:669-676.
23. Armstrong TS, Mendoza T, Gning I, et al. Validation of the M.D. Anderson Symptom Inventory Brain Tumor module (MDASI-BT). J Neurooncol. 2006;80:27-35.
24. Armstrong TS,Wefel JS, Gning I, et al. Congruence of primary brain tumor patient and caregiver symptom report. Cancer. 2012;118: 5026-5037.
25. Reardon DA, Galanis E, DeGroot JF, et al. Clinical trial end points for highgrade glioma: the evolving landscape. Neuro Oncol. 2011;13:353-361.
26. Wefel JS, Vardy J, Ahles T, et al. International cognition and cancer task force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol. 2011;12:703-708.
27. Reardon DA, Nayak L, DeAngelis LM, et al. P15.13: the Neurological Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration in the Radiological Assessment in Neuro-Oncology (RANO) criteria. Neuro Oncol. 2014;16(suppl 2):ii76.
28. Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol. 2003;30(12): 2563-2571.